TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
18 hedge funds and large institutions have $3.05M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 3 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
42% more capital invested
Capital invested by funds: $2.14M → $3.05M (+$906K)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
+$117K |
| 2 |
Two Sigma Investments
New York
|
+$105K |
| 3 |
Renaissance Technologies
New York
|
+$90.4K |
| 4 |
Millennium Management
New York
|
+$84.8K |
| 5 |
Two Sigma Advisers
New York
|
+$83.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$57K |
| 2 |
PCM
Puissance Capital Management
New York
|
-$31K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$16.4K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$1K |
TCON Hedge Fund Activity: Q2 2020 in Review
18 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2020, worth a combined $3.05M — up 42% from $2.14M a quarter earlier.
Fund positioning in TCON was balanced in Q2 2020: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 1 trimmed.
The largest buyer was Telemetry Investments, adding an estimated $117K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $57K sold.
- 18 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $3.05M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2020, up 42% quarter-over-quarter.
- 3 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 3 closed out, a net change of 0 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was Telemetry Investments, an estimated $117K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was JP Morgan Chase, an estimated $57K sold.
Based on aggregated 13F filings for Q2 2020.